Statistics from Altmetric.com
Q Is aripiprazole an effective and tolerable treatment for schizophrenia?
Systematic review with meta-analysis.
Cochrane Schizophrenia Group Register (August 2004), hand searches of relevant journals, conference proceedings and reference lists, US Food and Drug Administration website, searches of pharmaceutical industry material and internet resources, and contact with aripiprazole manufacturers.
Study selection and analysis:
Randomised controlled trials (RCTs) were included if they compared aripiprazole (any dose) versus either placebo or other antipsychotic drug for the treatment of schizophrenia or schizophrenia-like psychoses. Relative risks (RR), and confidence intervals (CI) were calculated using a conservative intention-to-treat analysis and a random effects model.
Primary outcome: relapse. Other outcomes: withdrawal rate, death, adverse effects (headache, anxiety, insomnia, …
For correspondence: Dr H G El-Sayeh, Briary Wing, Harrogate District Hospital, Lancaster Park Road, Harrogate HG2 7SX, UK;
Sources of funding: University of Leeds, Ospedale Niguarde Ca’Granda.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.